Discover how we have turned around clinical trials for our clients
Accelerating the patient enrollment rate in a global rare disease trial despite the COVID-19 pandemic
Rare Disease: A Phase IIa Lupus Case Study
A global pharmaceutical company instructed Innovative Trials to support them in screening 735 patients and enrolling 249 patients for a complex global Lupus (LSE) study. Innovative Trials deployed a ‘boot-on-the-ground’ approach via their Clinical Enrollment Managers (CEMs) to deliver Site Enrollment Optimization Support paired with study branding & development of patient recruitment materials, study website & prescreening creation, and digital campaign execution.
Increasing patient randomisation rate by 200% for a Top 5 global pharma
Phase IIa Moderate to Severe Hidradenitis Suppurativa Case Study
A Top 5 pharma was looking to randomise 192 patients with moderate to severe HS at 60 sites across the USA, Canada and Australia. Innovative Trials was asked to provide support with patient recruitment and demonstrated that a multi-faceted patient-centric recruitment strategy with a focus on optimising site engagement can overcome potential obstacles and deliver faster, more efficient results.
Clinical Enrolment Managers (CEMs) supported sites showed a 181% increase in pre-screening rates following calls.
Paediatric Case Study: Type II Diabetes Phase IIIa
The study sponsor approached Innovative Trials to aid recruitment activities on this Phase IIIa rescue study, where targets were not being met. Despite challenging inclusion criteria, this study saw success in recruiting children and adolescents with Type II Diabetes.
Sites receiving diversity outreach visits saw a 63% increase in randomised patients than those without.
Diversity Outreach Case Study: Active SLE Phase III
Innovative Trials’ services were rolled out to support the study sponsor with community outreach for this Phase III Active Systemic Lupus Erythematosus (SLE) study. The study looked to increase awareness access to clinical trials amongst diverse communities.
Rapid implementation of a 2-month rescue pilot led to a 113% increase in randomisation rates, getting the study back on schedule.
Rescue Case Study: Oncology Phase III
A leading biopharmaceutical company approached Innovative Trials to increase enrolment for their phase III study of Metastatic Colorectal Cancer (mCRC). The study needed to enroll 1250 eligible patients, however sites were experiencing severe enrolment fatigue and enrolment was lagging.
Community Outreach Boosted Enrolment for a Birth Control Study.
Community Outreach Case Study: Women’s Health Phase III
Innovative Trials were approached to support a mid size pharmaceutical company to accelerate enrolment for a Phase III birth control study in the US. The study needed to enrol 1357 healthy women aged 18-35 in a 7 month period.